David Crowe (Dave Crowe)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 2

Top Topics

Protein Protein

Top Venues

Nucleic acid therapeutics

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Ekta Patel, Natalia V Malkova, David Crowe, Magali Pederzoli-Ribeil, Damiano Fantini, Manoussa Fanny, Hanumantha Rao Madala, Kurt A Jenkins, Oleg Yerov, Justin M Greene, Wilson Guzman, Caitlin O'Toole, Jacob Taylor, Rebekah K O'Donnell, Parker Johnson, Bernard B Lanter, Brian Ames, Jia Chen, Sallyann Vu, Hsin-Jung Wu, Susan Cantin, Megan McLaughlin, Yu-Shan S Hsiao, Dheeraj S Tomar, Raphael Rozenfeld, Lakshmanan Thiruneelakantapillai, Ronan C O'Hagan, Benjamin Nicholson, Jennifer O'Neil, Carl Uli Bialucha
XTX301, a tumor-activated Interleukin-12 has the potential to widen the therapeutic index of IL-12 treatment for solid tumors as evidenced by pre-clinical studies. Molecular cancer therapeutics (2023)
Scott P Henry, Cecilia Arfvidsson, Josh Arrington, Jasna Canadi, David Crowe, Shalini Gupta, Sabine Lohmann, Benoit Massonnet, Daniel Mytych, Tina Rogers, Hobart Rogers, Chris Stebbins, Craig Stovold, Daniela Verthelyi, Adam Vigil, Chi Xuan, Yuanxin Xu, Rosie Yu, Thomas Klem
Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs. Nucleic acid therapeutics 32 (5) (2022)